Randomized, Placebo-controlled Parallel Group Clinical Trial of Nicotinamide Riboside to Evaluate NAD+ Levels in Individuals With Persistent Cognitive and Physical Symptoms After COVID-19 Illness (Long-COVID)

Who is this study for? Adult patients with history of COVID-19
What treatments are being studied? Niagen
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The study will assess whether Niagen, a safe dietary supplement, improves recovery of COVID-19 related symptoms in individuals who were infected at least 2 months prior to study entry (Long-COVID Long-haulers). 60% of participants will receive Niagen and 40% will receive PBO. Outcomes will consist of standardized cognitive, neuropsychiatric, physical, functional and biomarker assessments.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: No
View:

• History of SARS-CoV-2 PCR+ at least 2 months prior to study entry;

• SARS-CoV-2 negative (PCR) at study entry;

• Persistent cognitive difficulties (esp. brain fog) that began around the time of the acute COVID-19;

• At least two neurological and/or physical symptoms that started with COVID-19 infection and are ongoing at study entry, including fatigue, weakness, headache, loss of smell, tingling/numbness, shortness of breath, loss of appetite, palpitations/tachycardia, hair loss, musculoskeletal and/or chest pain;

• Willing and able to consent, complete all assessment and study procedures;

• Not pregnant or lactating.

Locations
United States
Massachusetts
Clinical Translational Research Unit
Recruiting
Boston
Contact Information
Primary
Isabel Abril, BA
COVIDNiagenStudy@mgh.harvard.edu
617-726-9915
Time Frame
Start Date: July 22, 2021
Estimated Completion Date: December 31, 2023
Participants
Target number of participants: 100
Treatments
Placebo Comparator: Placebo
Placebo: 40 participants will take placebo in the form of a capsule.
Experimental: Niagen
Supplement: 60 participants will take Niagen 2000mg in the form of capsules daily.
Authors
Edmarie Guzman-Velez
Sponsors
Leads: Massachusetts General Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials